Negative Symptome der Schizophrenie

Von Henry A. Nasrallah, MD
Geschäftsführender Vizepräsident und wissenschaftlicher Direktor der CURESZ-Stiftung

Schizophrenia is a complex neuropsychiatric syndrome with multiple symptom domains. The most recognizable symptom cluster is psychosis (classically, hallucinations and delusions)  which is the reason many patients are initially hospitalized. However, most patients with schizophrenia also suffer from three other symptom clusters including negative symptoms (deficits in normal brain function such as lack of motivation and interest that impair social and vocational functioning), cognitive impairments and mood symptoms. In fact, the negative and cognitive symptoms are what causes functional disability, even after the psychotic symptoms subside with antipsychotic medications.

Negative symptoms were not widely recognized until the 1980’s. Prior to that, the focus in schizophrenia was on the psychotic symptoms (hallucinations and delusions). The persistence of negative symptoms after the psychosis is controlled led to many studies that characterized the various negative symptoms.

Im Folgenden sind die negativen Symptome der Schizophrenie aufgeführt, die normalerweise eher von der Familie oder dem Psychiater als von den Patienten selbst beobachtet werden:

1. AFFECT PATHOLOGY This refers to a flat, blunted or restricted facial expression. In addition, other manifestations include poor eye contact, decreased spontaneous movements, monotone speech (referred to as aprosody), and failure to recognize the facial expression of other people (such as neutral, angry, sad, disgusted or anxious).

2. ALOGIA Which is a reduction in the quantity of thought, and poverty of speech, including speaking in monosyllables rather than sentences. Sometimes, patients may suddenly stop speaking in mid-sentence (called “blocking”) which is an interruption of thought. There is often a prolonged pause before responding to a question.

3. ASSOZIALITÄT Das ist das Fehlen oder die Verringerung des Interesses an sozialen Beziehungen oder Interaktionen mit anderen. Die Patienten sind auch nicht in der Lage, Intimität oder Nähe zu anderen zu empfinden.

4. AVOLITION UND Apathie Das ist der Verlust der Fähigkeit, eine zielgerichtete Aktivität zu initiieren oder daran festzuhalten. Dazu gehört, nicht zu baden, sich schlecht zu pflegen und den ganzen Tag nichts zu tun, was oft als „Faulheit“ missverstanden wird.

5. ANHEDONIA Which is the loss or reduction of the capacity to experience pleasure, manifested by lack of interest in enjoyable activities. This is also a decrease in sexual activity, interest or enjoyment. Unlike the anhedonia of depression, it is not reversible in most patients.

6. UNAUFMERKSAMKEIT Das ist die Unfähigkeit, eine Aufgabe oder ein Engagement für einen angemessenen Zeitraum aufrechtzuerhalten. Der Patient scheint in eine innere Welt vertieft zu sein, unter Ausschluss äußerer Aufgaben.

7. ANOSOGNOSIA Also referred to as non-awareness of illness. The patient lacks insight into their illness or disability. It can also be regarded as a cognitive deficit. This lack of insight prevents patients from seeking treatment or help to alleviate symptoms or to solve personal problems. Anosognosia can be reversible with continuous adherence to antipsychotic therapy.

Researchers sometimes classify the above negative symptoms into two major subdivisions:

1. Verminderter Ausdruck, der affektive Abflachung und Alogie umfasst, und

2. Apathie / Avolition, die Motivationsmangel und Asozialität umfasst.

In contrast to “positive” psychotic symptoms for which dozens of medications are available, there are no treatments yet for negative symptoms. It is a huge unmet need in the field of schizophrenia. So far, many attempts have been futile in developing a pharmacological treatment for negative symptoms. Thus, psychotherapy is the main approach to help patients recognize and overcome their negative symptoms. Occupational and recreational therapies can also be helpful. There are a couple of promising medications on the horizon. However, the FDA has not approved any of these yet.